Metabolism of flavonoids in human: A comprehensive review

Current Drug Metabolism

Volumn 15, Issue 1, 2014, Pages 48-61

  Chen, Zhongjian ^a,b   Zheng, Shirui ^b   Li, Liping ^b   Jiang, Huidi ^b  

^a ZHEJIANG CANCER HOSPITAL   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Efflux transporter; Flavonoid; Glucuronidation; Metabolism; Methylation; Sulfation

Indexed keywords

APIGENIN; APIGETRIN; CATECHIN; DAIDZEIN; DELPHINIDIN; ERIODICTYOL; FLAVANOL DERIVATIVE; FLAVANONE; FLAVANONE DERIVATIVE; FLAVONE DERIVATIVE; FLAVONOID; FLAVONOID GLYCOSIDE; FLAVONOL; FLAVONOL DERIVATIVE; GALLOCATECHIN; GENISTEIN; GLUCOSIDE; GLUCURONOSYLTRANSFERASE; HESPERETIN; ISOFLAVONE; ISOFLAVONE DERIVATIVE; ISOQUERCITRIN; LUTEOLIN; LUTEOLIN 7 GLUCOSIDE; MYRICETIN; NARINGENIN; PHLORETIN; QUERCETIN; RUTOSIDE; UNINDEXED DRUG;

ANTIDIARRHEAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BLACK CURRANT; DEMETHYLATION; DRUG ABSORPTION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG TRANSFORMATION; ENTEROHEPATIC CIRCULATION; GLUCURONIDATION; GOLGI COMPLEX; GRAPEFRUIT; HERBAL MEDICINE; HYDROXYLATION; INCIDENCE; INTESTINE FLORA; METHYLATION; OXIDATION; REVIEW; SOYBEAN; SULFATION; SYSTEMIC CIRCULATION;

CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 ENZYME SYSTEM; FLAVONOIDS; GLUCURONOSYLTRANSFERASE; GLYCOSIDES; HUMANS; INTESTINES; SULFOTRANSFERASES;

EID: 84896324163     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920021501140218125020     Document Type: Review

References (138)

1. Del Rio, D.; Rodriguez-Mateos, A.; Spencer, J. P.; Tognolini, M.; Borges, G.; Crozier, A. Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. Antioxid. Redox Signal., 2013, 18, 1818-1892.
2. Lopez-Lazaro, M. Distribution and biological activities of the flavonoid luteolin. Mini Rev. Med. Chem., 2009, 9, 31-59.
3. Xiao, J.; Cao, H.; Wang, Y.; Zhao, J.; Wei, X. Glycosylation of dietary flavonoids decreases the affinities for plasma protein. J. Agric. Food Chem., 2009, 57, 6642-6648.
4. Kyle, J. A.; Sharp, L.; Little, J.; Duthie, G. G.; McNeill, G. Dietary flavonoid intake and colorectal cancer: a case-control study. Br. J. Nutr., 2010, 103, 429-436.
5. Adebamowo, C. A.; Cho, E.; Sampson, L.; Katan, M. B.; Spiegelman, D.; Willett, W. C.; Holmes, M. D. Dietary flavonols and flavonol-rich foods intake and the risk of breast cancer. Int. J. Cancer, 2005, 114, 628-633.
6. Chun, O. K.; Chung, S. J.; Song, W. O. Estimated dietary flavonoid intake and major food sources of U.S. adults. J. Nutr., 2007, 137, 1244-1252.
7. Chen, J.; Wang, S.; Jia, X.; Bajimaya, S.; Lin, H.; Tam, V. H.; Hu, M. Disposition of flavonoids via recycling: comparison of intestinal versus hepatic disposition. Drug Metab. Dispos., 2005, 33, 1777-1784.
8. Gu, L.; Kelm, M. A.; Hammerstone, J. F.; Beecher, G.; Holden, J.; Haytowitz, D.; Gebhardt, S.; Prior, R. L. Concentrations of proanthocyanidins in common foods and estimations of normal consumption. J. Nutr., 2004, 134, 613-617.
9. Scalbert, A.; Williamson, G., Dietary intake and bioavailability of polyphenols. J. Nutr., 2000, 130, 2073-2085.
10. Perez-Vizcaino, F.; Duarte, J. Flavonols and cardiovascular disease. Mol. Aspects Med., 2010, 31, 478-494.
11. Jacques, P. F.; Cassidy, A.; Rogers, G.; Peterson, J. J.; Meigs, J. B.; Dwyer, J. T. Higher Dietary Flavonol Intake Is Associated with Lower Incidence of Type 2 Diabetes. J. Nutr., 2013, 143, 1474-1480.
12. Xiao, J.; Kai, G.; Yamamoto, K.; Chen, X. Advance in dietary polyphenols as alpha-glucosidases inhibitors: a review on structureactivity relationship aspect. Crit. Rev. Food Sci. Nutr., 2013, 53, 818-836.
13. Xiao, J.; Ni, X.; Kai, G.; Chen, X. A review on structure-activity relationship of dietary polyphenols inhibiting alpha-amylase. Crit. Rev. Food Sci. Nutr., 2013, 53, 497-506.
14. Hussain, M.; Banerjee, M.; Sarkar, F. H.; Djuric, Z.; Pollak, M. N.; Doerge, D.; Fontana, J.; Chinni, S.; Davis, J.; Forman, J.; Wood, D. P.; Kucuk, O. Soy isoflavones in the treatment of prostate cancer. Nutr. Cancer, 2003, 47, 111-117.
15. Xin, H. L.; Zhai, X. F.; Zheng, X.; Zhang, L.; Wang, Y. L.; Wang, Z. Anti-inflammatory and analgesic activity of total flavone of Cunninghamia lanceolata. Molecules, 2012, 17, 8842-8850.
16. Vilaca, R.; Mendes, V.; Mendes, M. V.; Carreto, L.; Amorim, M. A.; de Freitas, V.; Moradas-Ferreira, P.; Mateus, N.; Costa, V. Quercetin protects Saccharomyces cerevisiae against oxidative stress by inducing trehalose biosynthesis and the cell wall integrity pathway. PLoS One, 2012, 7, e45494.
17. Shi, C.; Fan, L. Y.; Cai, Z.; Liu, Y. Y.; Yang, C. L. Cellular stress response in Eca-109 cells inhibits apoptosis during early exposure to isorhamnetin. Neoplasma, 2012, 59, 361-369.
18. Notas, G.; Nifli, A. P.; Kampa, M.; Pelekanou, V.; Alexaki, V. I.; Theodoropoulos, P.; Vercauteren, J.; Castanas, E. Quercetin accumulates in nuclear structures and triggers specific gene expression in epithelial cells. J. Nutr. Biochem., 2012, 23, 656-666.
19. Das, S.; Das, J.; Samadder, A.; Boujedaini, N.; Khuda-Bukhsh, A. R. Apigenin-induced apoptosis in A375 and A549 cells through selective action and dysfunction of mitochondria. Exp. Biol. Med. (Maywood), 2012, 237, 1433-1448.
20. Lucas, C. D.; Allen, K. C.; Dorward, D. A.; Hoodless, L. J.; Melrose, L. A.; Marwick, J. A.; Tucker, C. S.; Haslett, C.; Duffin, R.; Rossi, A. G. Flavones induce neutrophil apoptosis by downregulation of Mcl-1 via a proteasomal-dependent pathway. FASEB J., 2013, 27, 1084-1094.
21. Ray, P. D.; Huang, B. W.; Tsuji, Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal., 2012, 24, 981-990.
22. Jung, I. H.; Lee, Y. H.; Yoo, J. Y.; Jeong, S. J.; Sonn, S. K.; Park, J. G.; Ryu, K. H.; Lee, B. Y.; Han, H. Y.; Lee, S. Y.; Kim, D. Y.; Lee, H.; Oh, G. T. Ginkgo biloba extract (GbE) enhances the antiatherogenic effect of cilostazol by inhibiting ROS generation. Exp. Mol. Med., 2012, 44, 311-318.
23. Vitale, D. C.; Piazza, C.; Melilli, B.; Drago, F.; Salomone, S. Isoflavones: estrogenic activity, biological effect and bioavailability. Eur. J. Drug Metab. Pharmacokinet., 2013, 38, 15-25.
24. Chou, R. H.; Hsieh, S. C.; Yu, Y. L.; Huang, M. H.; Huang, Y. C.; Hsieh, Y. H. Fisetin Inhibits Migration and Invasion of Human Cervical Cancer Cells by Down-Regulating Urokinase Plasminogen Activator Expression through Suppressing the p38 MAPK-Dependent NF-kappaB Signaling Pathway. PLoS One, 2013, 8, e71983.
25. Liu, H.; Liu, K.; Huang, Z.; Park, C. M.; Thimmegowda, N. R.; Jang, J. H.; Ryoo, I. J.; He, L.; Kim, S. O.; Oi, N.; Lee, K. W.; Soung, N. K.; Bode, A. M.; Yang, Y.; Zhou, X.; Erikson, R. L.; Ahn, J. S.; Hwang, J.; Kim, K. E.; Dong, Z.; Kim, B. Y. A chrysin derivative suppresses skin cancer growth by inhibiting cyclindependent kinases. J. Biol. Chem., 2013, 288, 25924-25937.
26. Hu, B. B.; Wu, Z. S.; Cai, J.; Jiang, H. D. Determination of main flavone glycosides in Flos Chrysanthemi and observation of factors influenced contents. Zhongguo Zhong Yao Za Zhi, 2006, 31, 1772-1775.
27. Zhou, P.; Li, L. P.; Luo, S. Q.; Jiang, H. D.; Zeng, S. Intestinal absorption of luteolin from peanut hull extract is more efficient than that from individual pure luteolin. J. Agric. Food Chem., 2008, 56, 296-300.
28. Chuankhayan, P.; Rimlumduan, T.; Svasti, J.; Cairns, J. R. Hydrolysis of soybean isoflavonoid glycosides by Dalbergia betaglucosidases. J. Agric. Food Chem., 2007, 55, 2407-2412.
29. Kottra, G.; Daniel, H. Flavonoid glycosides are not transported by the human Na+/glucose transporter when expressed in Xenopus laevis oocytes, but effectively inhibit electrogenic glucose uptake. J. Pharmacol. Exp. Ther., 2007, 322, 829-835.
30. Hanske, L.; Loh, G.; Sczesny, S.; Blaut, M.; Braune, A. The bioavailability of apigenin-7-glucoside is influenced by human intestinal microbiota in rats. J. Nutr., 2009, 139, 1095-1102.
31. Rowland, A.; Miners, J. O.; Mackenzie, P. I. The UDPglucuronosyltransferases: their role in drug metabolism and detoxification. Int. J. Biochem. Cell Biol., 2013, 45, 1121-1132.
32. Polimanti, R.; Piacentini, S.; Manfellotto, D.; Fuciarelli, M. Human genetic variation of CYP450 superfamily: analysis of functional diversity in worldwide populations. Pharmacogenomics, 2012, 13, 1951-1960.
33. van de Waterbeemd, H. The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. Eur. J. Pharm. Sci., 1998, 7, 1-3.
34. Chen, Y.; Wang, J.; Jia, X.; Tan, X.; Hu, M. Role of intestinal hydrolase in the absorption of prenylated flavonoids present in Yinyanghuo. Molecules, 2011, 16, 1336-1348.
35. Day, A. J.; Canada, F. J.; Diaz, J. C.; Kroon, P. A.; McLauchlan, R.; Faulds, C. B.; Plumb, G. W.; Morgan, M. R.; Williamson, G. Dietary flavonoid and isoflavone glycosides are hydrolysed by the lactase site of lactase phlorizin hydrolase. FEBS Lett., 2000, 468, 166-170.
36. Hur, H. G.; Lay, J. O., Jr.; Beger, R. D.; Freeman, J. P.; Rafii, F. Isolation of human intestinal bacteria metabolizing the natural isoflavone glycosides daidzin and genistin. Arch. Microbiol., 2000, 174, 422-428.
37. Bokkenheuser, V. D.; Shackleton, C. H.; Winter, J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochem. J., 1987, 248, 953-956.
38. Lee, J. E.; Lee, S.; Sung, J.; Ko, G. Analysis of human and animal fecal microbiota for microbial source tracking. ISME J., 2011, 5, 362-365.
39. Simons, A. L.; Renouf, M.; Hendrich, S.; Murphy, P. A. Metabolism of glycitein (7,4'-dihydroxy-6-methoxy-isoflavone) by human gut microflora. J. Agric. Food Chem., 2005, 53, 8519-8525.
40. Yang, J.; Qian, D.; Jiang, S.; Shang, E. X.; Guo, J.; Duan, J. A. Identification of rutin deglycosylated metabolites produced by human intestinal bacteria using UPLC-Q-TOF/MS. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2012, 898, 95-100.
41. Braune, A.; Gutschow, M.; Engst, W.; Blaut, M. Degradation of quercetin and luteolin by Eubacterium ramulus. Appl. Environ. Microbiol., 2001, 67, 5558-5567.
42. Kim, D. H.; Jung, E. A.; Sohng, I. S.; Han, J. A.; Kim, T. H.; Han, M. J. Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch. Pharm. Res., 1998, 21, 17-23.
43. Liu, Y.; Dai, Y.; Xun, L.; Hu, M. Enteric disposition and recycling of flavonoids and ginkgo flavonoids. J. Altern. Complement. Med., 2003, 9, 631-640.
44. Heinonen, S. M.; Wahala, K.; Liukkonen, K. H.; Aura, A. M.; Poutanen, K.; Adlercreutz, H. Studies of the in vitro intestinal metabolism of isoflavones aid in the identification of their urinary metabolites. J. Agric. Food Chem., 2004, 52, 2640-2646.
45. Matthies, A.; Loh, G.; Blaut, M.; Braune, A. Daidzein and genistein are converted to equol and 5-hydroxy-equol by human intestinal Slackia isoflavoniconvertens in gnotobiotic rats. J. Nutr., 2012, 142, 40-46.
46. Wang, X. L.; Hur, H. G.; Lee, J. H.; Kim, K. T.; Kim, S. I. Enantioselective synthesis of S-equol from dihydrodaidzein by a newly isolated anaerobic human intestinal bacterium. Appl. Environ. Microbiol., 2005, 71, 214-219.
47. Nishide, Y.; Tadaishi, M.; Kobori, M.; Tousen, Y.; Kato, M.; Inada, M.; Miyaura, C.; Ishimi, Y. Possible role of S-equol on bone loss via amelioration of inflammatory indices in ovariectomized mice. J. Clin. Biochem. Nutr., 2013, 53, 41-48.
48. Nielsen, I. L.; Williamson, G. Review of the factors affecting bioavailability of soy isoflavones in humans. Nutr. Cancer, 2007, 57, 1-10.
49. Grabowski, G. A. Delivery of lysosomal enzymes for therapeutic use: glucocerebrosidase as an example. Expert Opin. Drug Deliv., 2006, 3, 771-782.
50. Day, A. J.; Gee, J. M.; DuPont, M. S.; Johnson, I. T.; Williamson, G. Absorption of quercetin-3-glucoside and quercetin-4'-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. Biochem. Pharmacol., 2003, 65, 1199-1206.
51. Noguchi, J.; Hayashi, Y.; Baba, Y.; Okino, N.; Kimura, M.; Ito, M.; Kakuta, Y. Crystal structure of the covalent intermediate of human cytosolic beta-glucosidase. Biochem. Biophys. Res. Commun., 2008, 374, 549-552.
52. Mitchelmore, C.; Troelsen, J. T.; Spodsberg, N.; Sjostrom, H.; Noren, O. Interaction between the homeodomain proteins Cdx2 and HNF1alpha mediates expression of the lactase-phlorizin hydrolase gene. Biochem. J., 2000, 346(Pt 2), 529-535.
53. Schwanck, B.; Behrendt, M.; Naim, H. Y.; Blaschek, W. Deglycosylation of individual flavonoids and flavonoid containing plant extracts by purified human intestinal lactase-phlorizin hydrolase (LPH). Planta Med., 2011, 77, 22.
54. Sesink, A. L.; Arts, I. C.; Faassen-Peters, M.; Hollman, P. C. Intestinal uptake of quercetin-3-glucoside in rats involves hydrolysis by lactase phlorizin hydrolase. J. Nutr., 2003, 133, 773-776.
55. Day, A. J.; DuPont, M. S.; Ridley, S.; Rhodes, M.; Rhodes, M. J.; Morgan, M. R.; Williamson, G. Deglycosylation of flavonoid and isoflavonoid glycosides by human small intestine and liver β- glucosidase activity. FEBS J., 1998, 436, 71-75.
56. Chang, Q.; Zuo, Z.; Chow, M. S.; Ho, W. K. Difference in absorption of the two structurally similar flavonoid glycosides, hyperoside and isoquercitrin, in rats. Eur. J. Pharm. Biopharm., 2005, 59, 549-555.
57. Yamada, M.; Tanabe, F.; Arai, N.; Mitsuzumi, H.; Miwa, Y.; Kubota, M.; Chaen, H.; Kibata, M. Bioavailability of glucosyl hesperidin in rats. Biosci. Biotechnol. Biochem., 2006, 70, 1386-1394.
58. Ader, P.; Block, M.; Pietzsch, S.; Wolffram, S. Interaction of quercetin glucosides with the intestinal sodium/glucose cotransporter (SGLT-1). Cancer Lett., 2001, 162, 175-180.
59. Walgren, R. A.; Lin, J. T.; Kinne, R. K.; Walle, T. Cellular uptake of dietary flavonoid quercetin 4'-beta-glucoside by sodiumdependent glucose transporter SGLT1. J. Pharmacol. Exp. Ther., 2000, 294, 837-843.
60. Williams, J. A.; Hyland, R.; Jones, B. C.; Smith, D. A.; Hurst, S.; Goosen, T. C.; Peterkin, V.; Koup, J. R.; Ball, S. E. Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab. Dispos., 2004, 32, 1201-1208.
61. Tukey, R. H.; Strassburg, C. P. Human UDPglucuronosyltransferases: metabolism, expression, and disease. Annu. Rev. Pharmacol. Toxicol., 2000, 40, 581-616.
62. Mackenzie, P. I.; Bock, K. W.; Burchell, B.; Guillemette, C.; Ikushiro, S.; Iyanagi, T.; Miners, J. O.; Owens, I. S.; Nebert, D. W. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet. Genomics, 2005, 15, 677-685.
63. Luo, C. F.; Cai, B.; Hou, N.; Yuan, M.; Liu, S. M.; Ji, H.; Xiong, L. G.; Xiong, W.; Luo, J. D.; Chen, M. S. UDPglucuronosyltransferase 1A1 is the principal enzyme responsible for puerarin metabolism in human liver microsomes. Arch. Toxicol., 2012, 86, 1681-1690.
64. Singh, R.; Wu, B.; Tang, L.; Hu, M. Uridine diphosphate glucuronosyltransferase isoform-dependent regiospecificity of glucuronidation of flavonoids. J. Agric. Food Chem., 2011, 59, 7452-7464.
65. Court, M. H.; Zhang, X.; Ding, X.; Yee, K. K.; Hesse, L. M.; Finel, M. Quantitative distribution of mRNAs encoding the 19 human UDP- glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica, 2012, 42, 266-277.
66. Bushey, R. T.; Dluzen, D. F.; Lazarus, P. Importance of UDPglucuronosyltransferases 2A2 and 2A3 in tobacco carcinogen metabolism. Drug Metab. Dispos., 2013, 41, 170-179.
67. Heydel, J. M.; Holsztynska, E. J.; Legendre, A.; Thiebaud, N.; Artur, Y.; Le Bon, A. M. UDP-glucuronosyltransferases (UGTs) in neuro-olfactory tissues: expression, regulation, and function. Drug Metab. Rev., 2010, 42, 74-97.
68. Nakamura, A.; Nakajima, M.; Yamanaka, H.; Fujiwara, R.; Yokoi, T. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab. Dispos., 2008, 36, 1461-1464.
69. Wright, B.; Gibson, T.; Spencer, J.; Lovegrove, J. A.; Gibbins, J. M. Platelet-mediated metabolism of the common dietary flavonoid, quercetin. PLoS One, 2010, 5, e9673.
70. Chen, Z. J.; Dai, Y. Q.; Kong, S. S.; Song, F. F.; Li, L. P.; Ye, J. F.; Wang, R. W.; Zeng, S.; Zhou, H.; Jiang, H. D. Luteolin is a rare substrate of human catechol-O-methyltransferase favoring a paramethylation. Mol. Nutr. Food Res., 2013, 57, 877-885.
71. Wu, B.; Basu, S.; Meng, S.; Wang, X.; Hu, M. Regioselective sulfation and glucuronidation of phenolics: insights into the structural basis. Curr. Drug Metab., 2011, 12, 900-916.
72. Lee, H. S.; Ji, H. Y.; Park, E. J.; Kim, S. Y. In vitro metabolism of eupatilin by multiple cytochrome P450 and UDPglucuronosyltransferase enzymes. Xenobiotica, 2007, 37, 803-817.
73. Maul, R.; Siegl, D.; Kulling, S. E. Glucuronidation of the red clover isoflavone irilone by liver microsomes from different species and human UDP-glucuronosyltransferases. Drug Metab. Dispos., 2011, 39, 610-616.
74. Walsky, R. L.; Bauman, J. N.; Bourcier, K.; Giddens, G.; Lapham, K.; Negahban, A.; Ryder, T. F.; Obach, R. S.; Hyland, R.; Goosen, T. C. Optimized assays for human UDP-glucuronosyltransferase (UGT) activities: altered alamethicin concentration and utility to screen for UGT inhibitors. Drug Metab. Dispos., 2012, 40, 1051-1065.
75. Boersma, M. G.; van der Woude, H.; Bogaards, J.; Boeren, S.; Vervoort, J.; Cnubben, N. H.; van Iersel, M. L.; van Bladeren, P. J.; Rietjens, I. M. Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem. Res. Toxicol., 2002, 15, 662-670.
76. Xie, S.; Chen, Y.; Chen, S.; Zeng, S. Structure-metabolism relationships for the glucuronidation of flavonoids by UGT1A3 and UGT1A9. J. Pharm. Pharmacol., 2011, 63, 297-304.
77. Wu, B.; Xu, B.; Hu, M. Regioselective glucuronidation of flavonols by six human UGT1A isoforms. Pharm. Res., 2011, 28, 1905-1918.
78. Xiao, J.; Hogger, P. Metabolism of dietary flavonoids in liver microsomes. Curr. Drug Metab., 2013, 14, 381-391.
79. Tang, L.; Ye, L.; Singh, R.; Wu, B.; Lv, C.; Zhao, J.; Liu, Z.; Hu, M. Use of glucuronidation fingerprinting to describe and predict mono- and dihydroxyflavone metabolism by recombinant UGT isoforms and human intestinal and liver microsomes. Mol. Pharm., 2010, 7, 664-679.
80. Lodi, F.; Jimenez, R.; Menendez, C.; Needs, P. W.; Duarte, J.; Perez-Vizcaino, F. Glucuronidated metabolites of the flavonoid quercetin do not auto-oxidise, do not generate free radicals and do not decrease nitric oxide bioavailability. Planta Med., 2008, 74, 741-746.
81. Stachulski, A. V.; Meng, X. Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides. Nat. Prod. Rep., 2013, 30, 806-848.
82. Naz, H.; Islam, A.; Waheed, A.; Ahmad, F.; Sly, W. S.; Hassan, M. I. Human beta-glucuronidase: Structure, Function and Application in Enzyme Replacement Therapy. Rejuvenation Res., 2013, 16(5), 352-63.
83. Lisiewicz, J.; Moszczynski, P. [Beta-glucuronidase in human peripheral blood cells]. Przegl Lek., 1982, 39, 815-820.
84. Bartholome, R.; Haenen, G.; Hollman, C. H.; Bast, A.; Dagnelie, P. C.; Roos, D.; Keijer, J.; Kroon, P. A.; Needs, P. W.; Arts, I. C. Deconjugation kinetics of glucuronidated phase II flavonoid metabolites by beta-glucuronidase from neutrophils. Drug Metab. Pharmacokinet., 2010, 25, 379-387.
85. Lee-Hilz, Y. Y.; Stolaki, M.; van Berkel, W. J.; Aarts, J. M.; Rietjens, I. M. Activation of EpRE-mediated gene transcription by quercetin glucuronides depends on their deconjugation. Food Chem. Toxicol., 2008, 46, 2128-2134.
86. Lodi, F.; Jimenez, R.; Moreno, L.; Kroon, P. A.; Needs, P. W.; Hughes, D. A.; Santos-Buelga, C.; Gonzalez-Paramas, A.; Cogolludo, A.; Lopez-Sepulveda, R.; Duarte, J.; Perez-Vizcaino, F. Glucuronidated and sulfated metabolites of the flavonoid quercetin prevent endothelial dysfunction but lack direct vasorelaxant effects in rat aorta. Atherosclerosis, 2009, 204, 34-39.
87. Smolarz, H. D.; Budzianowski, J.; Bogucka-Kocka, A.; Kocki, J.; Mendyk, E. Flavonoid glucuronides with anti-leukaemic activity from Polygonum amphibium L. Phytochem. Anal., 2008, 19, 506-513.
88. Williamson, G.; Aeberli, I.; Miguet, L.; Zhang, Z.; Sanchez, M. B.; Crespy, V.; Barron, D.; Needs, P.; Kroon, P. A.; Glavinas, H.; Krajcsi, P.; Grigorov, M. Interaction of positional isomers of quercetin glucuronides with the transporter ABCC2 (cMOAT, MRP2). Drug Metab. Dispos., 2007, 35, 1262-1268.
89. Day, A. J.; Bao, Y.; Morgan, M. R.; Williamson, G. Conjugation position of quercetin glucuronides and effect on biological activity. Free Radic. Biol. Med., 2000, 29, 1234-1243.
90. Kawai, Y.; Nishikawa, T.; Shiba, Y.; Saito, S.; Murota, K.; Shibata, N.; Kobayashi, M.; Kanayama, M.; Uchida, K.; Terao, J. Macrophage as a target of quercetin glucuronides in human atherosclerotic arteries: implication in the anti-atherosclerotic mechanism of dietary flavonoids. J. Biol. Chem., 2008, 283, 9424-9434.
91. Gamage, N.; Barnett, A.; Hempel, N.; Duggleby, R. G.; Windmill, K. F.; Martin, J. L.; McManus, M. E. Human sulfotransferases and their role in chemical metabolism. Toxicol. Sci., 2006, 90, 5-22.
92. Riches, Z.; Stanley, E. L.; Bloomer, J. C.; Coughtrie, M. W. Quantitative evaluation of the expression and activity of five major sulfotransferases (SULTs) in human tissues: the SULT "pie". Drug Metab. Dispos., 2009, 37, 2255-2261.
93. Nowell, S.; Falany, C. N. Pharmacogenetics of human cytosolic sulfotransferases. Oncogene, 2006, 25, 1673-1678.
94. Salman, E. D.; Kadlubar, S. A.; Falany, C. N. Expression and localization of cytosolic sulfotransferase (SULT) 1A1 and SULT1A3 in normal human brain. Drug Metab. Dispos., 2009, 37, 706-709.
95. Huang, C.; Chen, Y.; Zhou, T.; Chen, G., Sulfation of dietary flavonoids by human sulfotransferases. Xenobiotica, 2009, 39, 312-322.
96. Vaidyanathan, J. B.; Walle, T. Glucuronidation and sulfation of the tea flavonoid (-)-epicatechin by the human and rat enzymes. Drug Metab. Dispos., 2002, 30, 897-903.
97. Otake, Y.; Hsieh, F.; Walle, T. Glucuronidation versus oxidation of the flavonoid galangin by human liver microsomes and hepatocytes. Drug Metab. Dispos., 2002, 30, 576-581.
98. Mannisto, P. T.; Kaakkola, S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev., 1999, 51, 593-628.
99. Chen, Z.; Chen, M.; Pan, H.; Sun, S.; Li, L.; Zeng, S.; Jiang, H. Role of catechol-O-methyltransferase in the disposition of luteolin in rats. Drug Metab. Dispos., 2011, 39, 667-674.
100. Tunbridge, E. M.; Lane, T. A.; Harrison, P. J. Expression of multiple catechol-o-methyltransferase (COMT) mRNA variants in human brain. Am. J. Med. Genet. B Neuropsychiatr. Genet., 2007, 144B, 834-839.
101. Dousa, M. K.; Weinshilboum, R. M.; Muenter, M. D.; Offord, K. P.; Decker, P. A.; Tyce, G. M. L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients. J. Neural. Transm., 2003, 110, 899-910.
102. Mullen, W.; Graf, B. A.; Caldwell, S. T.; Hartley, R. C.; Duthie, G. G.; Edwards, C. A.; Lean, M. E.; Crozier, A. Determination of flavonol metabolites in plasma and tissues of rats by HPLCradiocounting and tandem mass spectrometry following oral ingestion of [2-(14)C] quercetin-4'-glucoside. J. Agric. Food Chem., 2002, 50, 6902-6909.
103. de Boer, V. C.; Dihal, A. A.; van der Woude, H.; Arts, I. C.; Wolffram, S.; Alink, G. M.; Rietjens, I. M.; Keijer, J.; Hollman, P. C. Tissue distribution of quercetin in rats and pigs. J. Nutr., 2005, 135, 1718-1725.
104. Chen, Z.; Tu, M.; Sun, S.; Kong, S.; Wang, Y.; Ye, J.; Li, L.; Zeng, S.; Jiang, H. The exposure of luteolin is much lower than that of apigenin in oral administration of Flos Chrysanthemi extract to rats. Drug Metab. Pharmacokinet., 2012, 27, 162-168.
105. Zhu, B. T.; Ezell, E. L.; Liehr, J. G. Catechol-O- methyltransferasecatalyzed rapid O-methylation of mutagenic flavonoids. Metabolic inactivation as a possible reason for their lack of carcinogenicity in vivo. J. Biol. Chem., 1994, 269, 292-299.
106. Lu, W. C.; Sheen, J. F.; Hwang, L. S.; Wei, G. J. Identification of 5,7,3',4'-tetramethoxyflavone metabolites in rat urine by the isotope-labeling method and ultrahigh-performance liquid chromatography-electrospray ionization-mass spectrometry. J. Agric. Food Chem., 2012, 60, 8123-8128.
107. Walle, U. K.; Walle, T. Bioavailable flavonoids: cytochrome P450- mediated metabolism of methoxyflavones. Drug Metab. Dispos., 2007, 35, 1985-1989.
108. Lin, N.; Sato, T.; Takayama, Y.; Mimaki, Y.; Sashida, Y.; Yano, M.; Ito, A. Novel anti-inflammatory actions of nobiletin, a citrus polymethoxy flavonoid, on human synovial fibroblasts and mouse macrophages. Biochem. Pharmacol., 2003, 65, 2065-2071.
109. Gradolatto, A.; Canivenc-Lavier, M. C.; Basly, J. P.; Siess, M. H.; Teyssier, C. Metabolism of apigenin by rat liver phase I and phase ii enzymes and by isolated perfused rat liver. Drug Metab. Dispos., 2004, 32, 58-65.
110. Tan, K. W.; Li, Y.; Paxton, J. W.; Birch, N. P.; Scheepens, A. Identification of novel dietary phytochemicals inhibiting the efflux transporter breast cancer resistance protein (BCRP/ABCG2). Food Chem., 2013, 138, 2267-2274.
111. Yang, Y.; Zhou, X.; Xiao, M.; Hong, Z.; Gong, Q.; Jiang, L.; Zhou, J. Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro. J. Huazhong Univ. Sci. Technol. Med. Sci., 2010, 30, 734-740.
112. Kim, Y. H.; Lee, Y. S.; Choi, E. M. Chrysoeriol isolated from Eurya cilliata leaves protects MC3T3-E1 cells against hydrogen peroxide-induced inhibition of osteoblastic differentiation. J. Appl. Toxicol., 2010, 30, 666-673.
113. Chan, B. C.; Ip, M.; Gong, H.; Lui, S. L.; See, R. H.; Jolivalt, C.; Fung, K. P.; Leung, P. C.; Reiner, N. E.; Lau, C. B. Synergistic effects of diosmetin with erythromycin against ABC transporter over-expressed methicillin-resistant Staphylococcus aureus (MRSA) RN4220/pUL5054 and inhibition of MRSA pyruvate kinase. Phytomedicine, 2013, 20, 611-614.
114. Hsu, Y. L.; Kuo, P. L. Diosmetin induces human osteoblastic differentiation through the protein kinase C/p38 and extracellular signal-regulated kinase 1/2 pathway. J. Bone Miner. Res., 2008, 23, 949-960.
115. Ding, L. L.; Zhang, J. J.; Dou, W. Effects of isorhamnetin on CYP3A4 and herb-drug interaction. Yao Xue Xue Bao, 2012, 47, 1006-1010.
116. Ku, S. K.; Kim, T. H.; Bae, J. S. Anticoagulant activities of persicarin and isorhamnetin. Vascul. Pharmacol., 2013, 58, 272-279.
117. Nicolini, F.; Burmistrova, O.; Marrero, M. T.; Torres, F.; Hernandez, C.; Quintana, J.; Estevez, F. Induction of G /M phase arrest and apoptosis by the flavonoid tamarixetin on human leukemia cells. Mol. Carcinog., 2013, [Epub ahead of print].
118. Androutsopoulos, V.; Wilsher, N.; Arroo, R. R.; Potter, G. A. Bioactivation of the phytoestrogen diosmetin by CYP1 cytochromes P450. Cancer Lett., 2009, 274, 54-60.
119. Androutsopoulos, V. P.; Spandidos, D. A. The flavonoids diosmetin and luteolin exert synergistic cytostatic effects in human hepatoma HepG2 cells via CYP1A-catalyzed metabolism, activation of JNK and ERK and P53/P21 up-regulation. J. Nutr. Biochem., 2013, 24, 496-504.
120. Wei, Y.; Wu, B.; Jiang, W.; Yin, T.; Jia, X.; Basu, S.; Yang, G.; Hu, M. Revolving door action of breast cancer resistance protein (BCRP) facilitates or controls the efflux of flavone glucuronides from UGT1A9-overexpressing HeLa cells. Mol. Pharm., 2013, 10, 1736-1750.
121. Wang, S. W.; Chen, J.; Jia, X.; Tam, V. H.; Hu, M. Disposition of flavonoids via enteric recycling: structural effects and lack of correlations between in vitro and in situ metabolic properties. Drug Metab. Dispos., 2006, 34, 1837-1848.
122. Wong, C. C.; Akiyama, Y.; Abe, T.; Lippiat, J. D.; Orfila, C.; Williamson, G. Carrier-mediated transport of quercetin conjugates: involvement of organic anion transporters and organic anion transporting polypeptides. Biochem. Pharmacol., 2012, 84, 564-570.
123. DeGorter, M. K.; Xia, C. Q.; Yang, J. J.; Kim, R. B. Drug transporters in drug efficacy and toxicity. Annu. Rev. Pharmacol. Toxicol., 2012, 52, 249-273.
124. van Zanden, J. J.; van der Woude, H.; Vaessen, J.; Usta, M.; Wortelboer, H. M.; Cnubben, N. H.; Rietjens, I. M. The effect of quercetin phase II metabolism on its MRP1 and MRP2 inhibiting potential. Biochem. Pharmacol., 2007, 74, 345-351.
125. Wong, C. C.; Botting, N. P.; Orfila, C.; Al-Maharik, N.; Williamson, G. Flavonoid conjugates interact with organic anion transporters (OATs) and attenuate cytotoxicity of adefovir mediated by organic anion transporter 1 (OAT1/SLC22A6). Biochem. Pharmacol., 2011, 81, 942-949.
126. Yang, Z.; Zhu, W.; Gao, S.; Yin, T.; Jiang, W.; Hu, M. Breast cancer resistance protein (ABCG2) determines distribution of genistein phase II metabolites: reevaluation of the roles of ABCG2 in the disposition of genistein. Drug Metab. Dispos., 2012, 40, 1883-1893.
127. Liu, W.; Feng, Q.; Li, Y.; Ye, L.; Hu, M.; Liu, Z. Coupling of UDP-glucuronosyltransferases and multidrug resistance-associated proteins is responsible for the intestinal disposition and poor bioavailability of emodin. Toxicol. Appl. Pharmacol., 2012, 265, 316-324.
128. Walgren, R. A.; Karnaky, K. J., Jr.; Lindenmayer, G. E.; Walle, T. Efflux of dietary flavonoid quercetin 4'-beta-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2. J. Pharmacol. Exp. Ther., 2000, 294, 830-836.
129. Walle, U. K.; Galijatovic, A.; Walle, T. Transport of the flavonoid chrysin and its conjugated metabolites by the human intestinal cell line Caco-2. Biochem. Pharmacol., 1999, 58, 431-438.
130. Zhang, L.; Lin, G.; Kovacs, B.; Jani, M.; Krajcsi, P.; Zuo, Z. Mechanistic study on the intestinal absorption and disposition of baicalein. Eur. J. Pharm. Sci., 2007, 31, 221-231.
131. Gao, C.; Zhang, H.; Guo, Z.; You, T.; Chen, X.; Zhong, D. Mechanistic studies on the absorption and disposition of scutellarin in humans: selective OATP2B1-mediated hepatic uptake is a likely key determinant for its unique pharmacokinetic characteristics. Drug Metab. Dispos., 2012, 40, 2009-2020.
132. Jeong, E. J.; Jia, X.; Hu, M. Disposition of formononetin via enteric recycling: metabolism and excretion in mouse intestinal perfusion and Caco-2 cell models. Mol. Pharm., 2005, 2, 319-328.
133. Ghibellini, G.; Leslie, E. M.; Brouwer, K. L. Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol. Pharm., 2006, 3, 198-211.
134. Wilkinson, G. R. Drug metabolism and variability among patients in drug response. N Engl. J. Med., 2005, 352, 2211-2221.
135. Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie, A. E.; Zeldin, D. C. The human intestinal cytochrome P450 "pie". Drug Metab. Dispos., 2006, 34, 880-886.
136. Androutsopoulos, V. P.; Papakyriakou, A.; Vourloumis, D.; Tsatsakis, A. M.; Spandidos, D. A. Dietary flavonoids in cancer therapy and prevention: substrates and inhibitors of cytochrome P450 CYP1 enzymes. Pharmacol. Ther., 2010, 126, 9-20.
137. Androutsopoulos, V. P.; Ruparelia, K.; Arroo, R. R.; Tsatsakis, A. M.; Spandidos, D. A. CYP1-mediated antiproliferative activity of dietary flavonoids in MDA-MB-468 breast cancer cells. Toxicology, 2009, 264, 162-170.
138. Wan, L.; Guo, C.; Yu, Q.; Li, Y.; Wang, X.; Chen, C. Quantitative determination of apigenin and its metabolism in rat plasma after intravenous bolus administration by HPLC coupled with tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 855, 286-289.